Isaac Blech
Founder bei X-Vax Technology, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Roger Pomerantz | M | 67 |
X-Vax Technology, Inc.
 X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | 10 Jahre |
| Dan Wachtler | M | 53 | 9 Jahre | |
| Christopher Sullivan | M | 40 | 6 Jahre | |
| Mary DiBiase | M | 63 | 7 Jahre | |
| Adam Mostafa | M | 44 | 6 Jahre | |
| Michael Wyzga | M | 69 | 6 Jahre | |
| Clare Khan | M | 72 |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | 6 Jahre |
| Shaun Holt | M | 46 |
Alveo Technologies, Inc.
 Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | 2 Jahre |
| Murray Stewart | M | 63 | 5 Jahre | |
| Jay Kranzler | M | 66 |
Regenovation, Inc.
 Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | - |
| Gunnar Magnus Modee Persson | M | 64 | 12 Jahre | |
| Gary Bridger | M | 61 | 6 Jahre | |
| David McGirr | M | 69 | 7 Jahre | |
| Thomas Kester | M | 77 | 8 Jahre | |
| Ulf Arne Wiinberg | M | 66 |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | - |
| Neil Gunn | M | 63 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | 3 Jahre |
| Robert Ruffolo | M | - |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | - |
| Glenn Rockman | M | 43 |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | 2 Jahre |
| William A. Haseltine | M | 79 |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | - |
| Brian Finn | M | 63 |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | - |
| Robin Steele | F | 68 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Sol Barer | M | 76 |
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 12 Jahre |
| Timothy Boris | M | 55 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 9 Jahre |
| Michael Messinger | M | 49 | 11 Jahre | |
| Philip C. Ranker | M | 64 | 7 Jahre | |
| Robert C. Moscato | M | 48 | 2 Jahre | |
| Jerold Howard Rubinstein | M | 86 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 5 Jahre |
| Cary Sucoff | M | 71 | 6 Jahre | |
| Vuong Trieu | M | 59 | 2 Jahre | |
| Uli Alf Hacksell | M | 74 | 5 Jahre | |
| Blake Paterson | M | 67 | 4 Jahre | |
| Andrew Pearlman | M | 73 | 14 Jahre | |
| Steven Gilman | M | 71 | 8 Jahre | |
| Jonathan Drew Shultz | M | 64 | 6 Jahre | |
| Julia Gregory | F | 71 | 4 Jahre | |
| Robert Nowinski | M | - | 5 Jahre | |
| Brian Piper | M | 52 | 5 Jahre | |
| Joseph Grano | M | 76 | 8 Jahre | |
| Joseph W. Ramelli | M | 55 | 6 Jahre | |
| Alex Minicucci | M | 45 | - | |
| Simon Pedder | M | 63 | 2 Jahre | |
| René Russo | M | 49 | 6 Jahre | |
| Federica O’Brien | F | 66 | 2 Jahre | |
| Joseph Proto | M | 68 | 6 Jahre | |
| Luke Wallace | M | 40 | - | |
| Kim Petry | F | 55 | - | |
| Kent F. Anson | M | 64 | - | |
| James Paul Collas | M | 62 | 4 Jahre | |
| Joel Kanter | M | 67 | 15 Jahre | |
| Michael Robert McCoy | M | 63 | 3 Jahre | |
| James Harrell | M | 54 | 4 Jahre | |
| Joseph Miller | M | 50 | 4 Jahre | |
| Nancy Phelan | F | 55 | 2 Jahre | |
| Steven Boyd | M | 43 | 5 Jahre | |
| Philip Donenberg | M | 63 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Alan Milinazzo | M | 64 | 3 Jahre | |
| John Catsimatidis | M | 75 | - | |
| Lisa Ricciardi | F | 64 | - | |
| Michael Gray | M | 53 | 3 Jahre | |
| Michael Cola | M | 64 | 7 Jahre | |
| Seymour G. Siegel | M | 81 | 5 Jahre | |
| William Hornung | M | 55 | 6 Jahre | |
| David J. Horin | M | 56 | 2 Jahre | |
| John Kaiser | M | 68 | 5 Jahre | |
| David Low | M | 65 | 9 Jahre | |
| Eric Scott Hipkins | M | 56 | 1 Jahre | |
| Scott Applebaum | M | 57 | 2 Jahre | |
| Michael Barrett | M | 81 | - | |
| R. Eric Teague | M | 54 | 1 Jahre | |
| Bill Gantz | M | 86 | 5 Jahre | |
| Frank J. Liddy | M | 57 | 2 Jahre | |
| Erik Emerson | M | 53 | 2 Jahre | |
| Amit Bhupendra Shah | M | 57 | 1 Jahre | |
| Raymond Schuch | M | - | 6 Jahre | |
| Anthony J. Sartor | M | 81 | 3 Jahre | |
| Stephen Simes | M | 72 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Brian Thompson | M | - | 1 Jahre | |
| Rhonda L. Stanley | F | 64 | 1 Jahre | |
| Kevin T. Carnahan | M | 66 | 6 Jahre | |
| Phillip Gutry | M | 50 | 6 Jahre | |
| David Scheinberg | M | 68 | 6 Jahre | |
| Ka Cheong Leong | M | 81 | 6 Jahre | |
| Rex Bright | M | 84 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| John Leaman | M | 51 | 3 Jahre | |
| Harvey Pitt | M | 79 | - | |
| Frank Torti | M | 45 | - | |
| Chris A. Nicolaidis | M | 62 | 5 Jahre | |
| Philippe Calais | M | 65 | 1 Jahre | |
| Patrick M. Kolenik | M | 75 | 9 Jahre | |
| James J. Loughlin | M | 81 | 4 Jahre | |
| Peter Greenleaf | M | 54 | 3 Jahre | |
| Mark L. Sandson | M | 83 | 4 Jahre | |
| Sheng Da Zan | M | 61 | - | |
| Robert J. Desantis | M | - | 2 Jahre | |
| Yael Schwartz | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 1 Jahre |
| Gary Allan Brukardt | M | 78 | 6 Jahre | |
| Donald Williams | M | 65 | 5 Jahre | |
| Barry Kappel | M | 48 | 6 Jahre | |
| John H. Eyler | M | 76 | 6 Jahre | |
| David Sherris | M | 71 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 97 | 97,00% |
| Israel | 4 | 4,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Isaac Blech
- Persönliches Netzwerk
